28 April 2020
“The WHO has put nine COVID-19 vaccines that are being developed in Russia on its list of promising options. These include six vaccines created by the Novosibirsk-based Vector State Research Center of Virology and Biotechnology… two vaccines developed by the Biocad company… and a vaccine made by the St. Petersburg Research Institute of Vaccines and Serums,” according to a statement from the Russian government’s coronavirus hotline.
According to the hotline, one of Vector’s versions is a peptide vaccine based on a platform that was previously used for creating a vaccine against the Ebola virus. Along with that, a subunit vaccine, a live vector vaccine based on the measles virus, a recombinant intranasal vaccine based on the influenza A virus, a vector vaccine based on the vesicular stomatitis virus and an mRNA vaccine are in the works.
Biocad has developed a live viral vector vaccine based on an attenuated flu virus (together with the Institute of Experimental Medicine) and a liposome encapsulated vaccine. The St. Petersburg Research Institute of Vaccines and Serums, in turn, has come up with a vaccine based on recombinant protein and nanoparticles.
Print14 March 2024
26 February 2024
NovaMedica team wishes you a Merry Christmas and a Happy New Year!
26 December 2023
Big Pharma’s ROI for drug R&D saw 'welcome' rebound in 2023: report
25 April 2024
Orphan drug market to reach $270B by 2028 : Evaluate
25 April 2024
Russian drug for the treatment of viral hepatitis will be exempt from duty in Mongolia
24 April 2024
PM Mishustin: “We need to increase the production of vital and essential drugs in Russia”
24 April 2024